Analysts See $-0.03 EPS for IsoRay, Inc. (ISR)

September 16, 2018 - By Mary Markley

IsoRay, Inc. (NYSEAMERICAN:ISR) LogoInvestors sentiment decreased to 0.5 in Q2 2018. Its down 0.90, from 1.4 in 2018Q1. It is negative, as 3 investors sold IsoRay, Inc. shares while 3 reduced holdings. 2 funds opened positions while 1 raised stakes. 3.35 million shares or 12.43% less from 3.82 million shares in 2018Q1 were reported.
Northern Trust reported 0% stake. Morgan Stanley accumulated 0% or 1,473 shares. Bancorporation Of Mellon Corp accumulated 0% or 67,416 shares. Auxier Asset Management has invested 0% of its portfolio in IsoRay, Inc. (NYSEAMERICAN:ISR). Royal National Bank Of Canada invested in 0% or 21,000 shares. Vanguard Grp Inc has invested 0% of its portfolio in IsoRay, Inc. (NYSEAMERICAN:ISR). Bridgeway Capital Management Inc reported 0% of its portfolio in IsoRay, Inc. (NYSEAMERICAN:ISR). Architects has invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Wells Fargo And Commerce Mn holds 0% in IsoRay, Inc. (NYSEAMERICAN:ISR) or 10,000 shares. 10,000 are held by Natl Bank Of America De. State Street holds 0% or 15,600 shares. Ifrah Financial Svcs holds 0.01% or 30,000 shares. California Employees Retirement Systems holds 117,100 shares. Geode Capital Mgmt Limited Liability Co accumulated 269,778 shares. Raymond James Fincl reported 30,000 shares or 0% of all its holdings.

Analysts expect IsoRay, Inc. (NYSEAMERICAN:ISR) to report $-0.03 EPS on September, 27.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.03 EPS. After having $-0.02 EPS previously, IsoRay, Inc.’s analysts see 50.00 % EPS growth. The stock decreased 0.21% or $0.001 during the last trading session, reaching $0.533. About 161,670 shares traded. IsoRay, Inc. (NYSEAMERICAN:ISR) has risen 1.90% since September 16, 2017 and is uptrending. It has underperformed by 13.72% the S&P500.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, makes, and sells isotope medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company has market cap of $35.89 million. The firm produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It currently has negative earnings. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.

IsoRay, Inc. (NYSEAMERICAN:ISR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.